Structure and Governance

IRICoR’s Board of Directors has solid experience in a number of key sectors: biopharma, government affairs, intellectual property, regulatory affairs and in venture capital, as well as in academia.

Chair

Since 2006, Jean-François Leprince has been a Managing Partner at CTI Life Sciences Fund, a private venture capital company funding Canadian and U.S. biotechnology companies.

After obtaining a chemical engineering degree from the Institut national supérieur de chimie industrielle, in Rouen (France), he started his working career at Dow Chemical Company in the Specialty Chemicals Division before joining the Pharmaceutical Division in 1978. In various management and operational roles, Mr Leprince has travelled extensively to Belgium, Switzerland, France and to the Middle-East, Africa and South-East Asia. With the sale of Marion Merrell Dow to Hoechst in 1995, Mr Leprince became the Managing Director of one of Hoechst Marion Roussel’s three subsidiaries in France. In 1998, Mr Leprince became President of Hoechst Marion Roussel Canada and then of Aventis Canada as a result of the merger between Hoechst Marion Roussel and Rhone Poulenc Rorer, a role he held until the end of 2004.

While President of Aventis Canada, he served on the Board of Directors of former Rx&D (Canada’s Research-Based Pharmaceutical Companies), now named Innovative Medicines Canada, and was appointed Chair in 2002.

Mr Leprince served as President & CEO of GLyPharma Therapeutic Inc., a Montreal-based CTI Life Sciences Fund portfolio company until its acquisition by Swiss-based Therachon AG in September 2018.

He serves as Director of ILKOS THERAPEUTIC INC., another CTI Life Sciences Fund portfolio company resulting from a partnership with Laboratoires Servier-France.

Mr Leprince also serves on the Board of AllerGen and most recently was elected as Chairman of the Board of IRICoR. Both organizations are funded by the Networks of Centres of Excellence of Canada (NCE).

Jean-François Leprince, B.ENG.Managing Partner, CTI Life Sciences Fund

Since 2006, Jean-François Leprince has been a Managing Partner at CTI Life Sciences Fund, a private venture capital company funding Canadian and U.S. biotechnology companies.

After obtaining a chemical engineering degree from the Institut national supérieur de chimie industrielle, in Rouen (France), he started his working career at Dow Chemical Company in the Specialty Chemicals Division before joining the Pharmaceutical Division in 1978. In various management and operational roles, Mr Leprince has travelled extensively to Belgium, Switzerland, France and to the Middle-East, Africa and South-East Asia. With the sale of Marion Merrell Dow to Hoechst in 1995, Mr Leprince became the Managing Director of one of Hoechst Marion Roussel’s three subsidiaries in France. In 1998, Mr Leprince became President of Hoechst Marion Roussel Canada and then of Aventis Canada as a result of the merger between Hoechst Marion Roussel and Rhone Poulenc Rorer, a role he held until the end of 2004.

While President of Aventis Canada, he served on the Board of Directors of former Rx&D (Canada’s Research-Based Pharmaceutical Companies), now named Innovative Medicines Canada, and was appointed Chair in 2002.

Mr Leprince served as President & CEO of GLyPharma Therapeutic Inc., a Montreal-based CTI Life Sciences Fund portfolio company until its acquisition by Swiss-based Therachon AG in September 2018.

He serves as Director of ILKOS THERAPEUTIC INC., another CTI Life Sciences Fund portfolio company resulting from a partnership with Laboratoires Servier-France.

Mr Leprince also serves on the Board of AllerGen and most recently was elected as Chairman of the Board of IRICoR. Both organizations are funded by the Networks of Centres of Excellence of Canada (NCE).

 

Members

Frédéric Alberro began his career in 1995 in the government of Quebec as International Affairs Advisor to the Ministry of Industry, Trade, Science and Technology of Quebec (MICST) and special advisor to the Coordination of major economic projects Center of the Executive Council of Quebec.

Enthusiast economic development of Quebec, he later served as economic advisor to the Premier of Quebec from 1998 to 2001, Director of Economic Affairs of the Québec Government Office in Boston from 2001 to 2003 and again economic adviser of Premier of Quebec in 2003 and of the leader of the official opposition from 2003 to 2005.Mr. Alberro then acts as spokesperson for the AMF from 2005 to 2007.After over 12 years in the public system, Mr. Alberro worked in economic associations respectively occupy the function of Vice President Québec of the Canadian Council of Grocery Distributors and Vice President Québec the Retail Canadian Council. Through that, he has served on several Board of Directors, including Québec Food Banks.

Since 2011, he is the Director Québec of the Innovative Medicines Canada (former Rx&D)

Mr. Alberro has a BA in Business Administration from the Business School of UQQM and holds a Master of International Affairs from École Supérieure de Commerce de Sophia-Antipolis (Nice, France).

Frederic_Alberro
Frédéric AlberroDirector Québec, Innovative Medicines Canada

Frédéric Alberro began his career in 1995 in the government of Quebec as International Affairs Advisor to the Ministry of Industry, Trade, Science and Technology of Quebec (MICST) and special advisor to the Coordination of major economic projects Center of the Executive Council of Quebec.

Enthusiast economic development of Quebec, he later served as economic advisor to the Premier of Quebec from 1998 to 2001, Director of Economic Affairs of the Québec Government Office in Boston from 2001 to 2003 and again economic adviser of Premier of Quebec in 2003 and of the leader of the official opposition from 2003 to 2005.Mr. Alberro then acts as spokesperson for the AMF from 2005 to 2007.After over 12 years in the public system, Mr. Alberro worked in economic associations respectively occupy the function of Vice President Québec of the Canadian Council of Grocery Distributors and Vice President Québec the Retail Canadian Council. Through that, he has served on several Board of Directors, including Québec Food Banks.

Since 2011, he is the Director Québec of the Innovative Medicines Canada (former Rx&D)

Mr. Alberro has a BA in Business Administration from the Business School of UQQM and holds a Master of International Affairs from École Supérieure de Commerce de Sophia-Antipolis (Nice, France).

Dr. Nadine Beauger is President and CEO of IRICoR, a Centre of Excellence in Commercialization and Research specializing in drug discovery in oncology and related areas, based at IRIC/University of Montreal. Under her leadership, Dr. Beauger has raised significant funding for her organization through federal and provincial government programs among other sources. IRICoR is rapidly expanding its project portfolio, providing academics with its tailor-made funding and support towards increasing their projects’ value and establishing strong partnerships with the private sector for innovative therapeutic solutions to reach the market faster.

Before this appointment, Dr. Beauger was Vice-President – Scientific Liaison (intellectual property (IP), academia-industry relations) at that same organization that she joined in 2009. She was instrumental at building IRICoR’s project portfolio and related IP practice and strategy, which have led to successful licensing agreements and partnerships with industry. She had brought to IRICoR over 15 years of experience in technology assessment and transfer, venture capital, IP and project portfolio management, due diligence, and clinical and biotechnological research with thorough experience in both the private and the academic sectors.

Dr. Beauger began her career as a Patent Consultant at Robic, a Montreal-based IP boutique, where she undertook drafting, prosecution and IP strategic management. She went on as Associate at VantagePoint Venture Partners (now VantagePoint Capital Partners), a leading California-headquartered venture capital firm with more than $4 billion under management. Just prior to joining IRICoR, Dr. Beauger was Business Development Manager at Paladin Labs Inc, a top specialty pharmaceutical company based in Montreal (now an Endo international company).

She holds a Ph.D. in Biomedical Sciences (Hematology and Oncology), an M.Sc. in Cellular Biopathology from Université de Montréal and a B.Sc. in Anatomy from McGill University. She also holds an MBA degree from HEC Montréal (Excellence Studentship Award and Best Speaker Award). Dr. Beauger has been an invited speaker at a number of national and international events and is a Board member of CHU Ste-Justine Foundation, ExCellThera, one of IRICoR’s spin-off companies and a clinical-stage cell and molecular medicine company and Immune BioSolutions, a Sherbrooke-based innovative biotech specialized in antibody production.

Nadine Beauger, Ph.D., MBAPresident & Chief Executive Officer

Dr. Nadine Beauger is President and CEO of IRICoR, a Centre of Excellence in Commercialization and Research specializing in drug discovery in oncology and related areas, based at IRIC/University of Montreal. Under her leadership, Dr. Beauger has raised significant funding for her organization through federal and provincial government programs among other sources. IRICoR is rapidly expanding its project portfolio, providing academics with its tailor-made funding and support towards increasing their projects’ value and establishing strong partnerships with the private sector for innovative therapeutic solutions to reach the market faster.

Before this appointment, Dr. Beauger was Vice-President – Scientific Liaison (intellectual property (IP), academia-industry relations) at that same organization that she joined in 2009. She was instrumental at building IRICoR’s project portfolio and related IP practice and strategy, which have led to successful licensing agreements and partnerships with industry. She had brought to IRICoR over 15 years of experience in technology assessment and transfer, venture capital, IP and project portfolio management, due diligence, and clinical and biotechnological research with thorough experience in both the private and the academic sectors.

Dr. Beauger began her career as a Patent Consultant at Robic, a Montreal-based IP boutique, where she undertook drafting, prosecution and IP strategic management. She went on as Associate at VantagePoint Venture Partners (now VantagePoint Capital Partners), a leading California-headquartered venture capital firm with more than $4 billion under management. Just prior to joining IRICoR, Dr. Beauger was Business Development Manager at Paladin Labs Inc, a top specialty pharmaceutical company based in Montreal (now an Endo international company).

She holds a Ph.D. in Biomedical Sciences (Hematology and Oncology), an M.Sc. in Cellular Biopathology from Université de Montréal and a B.Sc. in Anatomy from McGill University. She also holds an MBA degree from HEC Montréal (Excellence Studentship Award and Best Speaker Award). Dr. Beauger has been an invited speaker at a number of national and international events and is a Board member of CHU Ste-Justine Foundation, ExCellThera, one of IRICoR’s spin-off companies and a clinical-stage cell and molecular medicine company and Immune BioSolutions, a Sherbrooke-based innovative biotech specialized in antibody production.

Mr. Bernier is co-founder and Managing Partner at Teralys Capital. He is a highly respected venture capitalist, entrepreneur and investor who has helped shape the Canadian technological innovation scene. Through a 35-year career of contributions to the high-tech community, he has been actively involved in more than a dozen emerging high-tech companies as founder or angel investor as well as Senior Vice-President of the Fonds de solidarité FTQ. Mr. Bernier’s widely valued wisdom and experience continue to define, develop and implement a new approach to venture capital in Canada and abroad. He serves on the board of PolyFinances, InnoCité Montréal, Quartier de l’Innovation, IRIC and he also does philanthropy work.

Mr. Bernier holds a Bachelor’s degree in Industrial Engineering from École polytechnique de Montréal (B.A.Sc.)

Jacques_Bernier
Jacques Bernier, B.ENGCo-founder and Managing Partner, Teralys Capital

Mr. Bernier is co-founder and Managing Partner at Teralys Capital. He is a highly respected venture capitalist, entrepreneur and investor who has helped shape the Canadian technological innovation scene. Through a 35-year career of contributions to the high-tech community, he has been actively involved in more than a dozen emerging high-tech companies as founder or angel investor as well as Senior Vice-President of the Fonds de solidarité FTQ. Mr. Bernier’s widely valued wisdom and experience continue to define, develop and implement a new approach to venture capital in Canada and abroad. He serves on the board of PolyFinances, InnoCité Montréal, Quartier de l’Innovation, IRIC and he also does philanthropy work.

Mr. Bernier holds a Bachelor’s degree in Industrial Engineering from École polytechnique de Montréal (B.A.Sc.)

Catherine Bouchard has more than ten years of experience in healthcare equity research. She joined la Caisse de dépôt et placement du Québec in March 2012 as senior healthcare analyst. With her team, she is responsible of developing fundamental and investable perspectives on the global healthcare sector and to orient decision-makers accordingly, including portfolio managers, private equity teams, investment committees and supervisory boards. She uses her broad knowledge to assess and recommend stocks, bonds or specialized assets (royalties, real estate). Prior to joining CDPQ, Ms. Bouchard spent five years at Valeurs Mobilières Banque Laurentienne, where she was the lead analyst covering healthcare stocks. She holds a MBA and a M.Sc. in Biomedical Sciences.

Catherine Bouchard, MSc, MBADirector Healthcare Research, Caisse de dépôt et placement du Québec

Catherine Bouchard has more than ten years of experience in healthcare equity research. She joined la Caisse de dépôt et placement du Québec in March 2012 as senior healthcare analyst. With her team, she is responsible of developing fundamental and investable perspectives on the global healthcare sector and to orient decision-makers accordingly, including portfolio managers, private equity teams, investment committees and supervisory boards. She uses her broad knowledge to assess and recommend stocks, bonds or specialized assets (royalties, real estate). Prior to joining CDPQ, Ms. Bouchard spent five years at Valeurs Mobilières Banque Laurentienne, where she was the lead analyst covering healthcare stocks. She holds a MBA and a M.Sc. in Biomedical Sciences.

 

Michel Bouvier holds a B.Sc. in biochemistry (1979) and a Ph.D in Neurological Sciences (1985) from the Université de Montréal and obtained post-doctoral training (1985-89) at Duke University under the supervision of Dr. R.J. Lefkowitz (Nobel prize Chemistry 2012). He is professor of Biochemistry and Molecular Medicine at the Faculty of Medicine of the Université de Montréal and principal investigator and at the Institute for Research in Immunology and Cancer. Dr. Bouvier is a world-renowned expert in the field of cell signalling and G protein-coupled receptors (GPCR) and made seminal contributions to our understanding of this major class of drug targets. His work on GPCR regulation led to paradigm shifts (inverse agonism, pharmacological chaperones, GPCR oligomerization, pluridimensionality of signalling), which coupled to his pioneering of bioluminescence resonance energy transfer (BRET) approaches, have direct impacts on drug discovery.

He is the author of over 260 scientific papers which received over 24,000 citations and delivered more than 400 invited conferences. He also holds 10 patents. His publications received more than 18,000 citations, leading to a Hirsh (h) index of 74 and his introduction on the 2014 Thomson Reuters’ list of the most cited scientists. His work was recognized by many awards, including his induction to the Academy of Sciences of the Royal Society of Canada in 2014. He trained 48 graduate students and 36 post-doctoral fellows, many of whom now hold professor and researcher positions around the world.

He currently holds the Canada research Chair in Signal Transduction and Molecular Pharmacology and is the general director of the Institute of Research in Immunology and Cancer.

Michel Bouvier is the Chief Executive Officer of IRIC, Deputy Vice-Rector Research, Discovery,Creation and Innovation at UdeM, and co-funder of IRICoR.

Michel_Bouvier
Michel Bouvier, Ph.D., FCAHS, FRSCCEO, Institute of Research in Immunology and Cancer

Michel Bouvier holds a B.Sc. in biochemistry (1979) and a Ph.D in Neurological Sciences (1985) from the Université de Montréal and obtained post-doctoral training (1985-89) at Duke University under the supervision of Dr. R.J. Lefkowitz (Nobel prize Chemistry 2012). He is professor of Biochemistry and Molecular Medicine at the Faculty of Medicine of the Université de Montréal and principal investigator and at the Institute for Research in Immunology and Cancer. Dr. Bouvier is a world-renowned expert in the field of cell signalling and G protein-coupled receptors (GPCR) and made seminal contributions to our understanding of this major class of drug targets. His work on GPCR regulation led to paradigm shifts (inverse agonism, pharmacological chaperones, GPCR oligomerization, pluridimensionality of signalling), which coupled to his pioneering of bioluminescence resonance energy transfer (BRET) approaches, have direct impacts on drug discovery.

He is the author of over 260 scientific papers which received over 24,000 citations and delivered more than 400 invited conferences. He also holds 10 patents. His publications received more than 18,000 citations, leading to a Hirsh (h) index of 74 and his introduction on the 2014 Thomson Reuters’ list of the most cited scientists. His work was recognized by many awards, including his induction to the Academy of Sciences of the Royal Society of Canada in 2014. He trained 48 graduate students and 36 post-doctoral fellows, many of whom now hold professor and researcher positions around the world.

He currently holds the Canada research Chair in Signal Transduction and Molecular Pharmacology and is the general director of the Institute of Research in Immunology and Cancer.

Michel Bouvier is the Chief Executive Officer of IRIC, Deputy Vice-Rector Research, Discovery,Creation and Innovation at UdeM, and co-funder of IRICoR.

In his role as President & CEO of BIOTECanada Andrew is responsible for the day-to-day operations of the Association. In this capacity, he is the primary spokesperson for Canada’s biotech industry communicating on the industry’s behalf with government, regulators, international bodies, media and the Canadian public. He also ensures BIOTECanada plays a central role in partnership with Government in the development of policy relating to Canada’s biotech sector and the member companies of BIOTECanada.

Prior to joining BIOTECanada, Andrew served from 2004-2012 as Vice President, Public Affairs and International Trade and Vice President, Government Relations and Communications for the Forestry Products Association of Canada. In those roles he held responsibility for the Association’s government relations, communications, media relations, advertising and international trade undertakings. From 1993-2004 he held the position of Assistant Vice-President, Government Relations with the Canadian Life and Health Insurance Association. Between 1989 and 1993 Andrew held political assistant positions with a Member of Parliament and the Minister of State (Finance).

Andrew Casey is a native of Montreal, Quebec. After attending Loyola High School (Montreal) and St. Lawrence CEGEP (Quebec City) he graduated from Carleton University (Ottawa) with a Bachelor of Arts degree in Political Science.

Andre_Casey
Andrew CaseyPresident and CEO, BIOTECanada

In his role as President & CEO of BIOTECanada Andrew is responsible for the day-to-day operations of the Association. In this capacity, he is the primary spokesperson for Canada’s biotech industry communicating on the industry’s behalf with government, regulators, international bodies, media and the Canadian public. He also ensures BIOTECanada plays a central role in partnership with Government in the development of policy relating to Canada’s biotech sector and the member companies of BIOTECanada.

Prior to joining BIOTECanada, Andrew served from 2004-2012 as Vice President, Public Affairs and International Trade and Vice President, Government Relations and Communications for the Forestry Products Association of Canada. In those roles he held responsibility for the Association’s government relations, communications, media relations, advertising and international trade undertakings. From 1993-2004 he held the position of Assistant Vice-President, Government Relations with the Canadian Life and Health Insurance Association. Between 1989 and 1993 Andrew held political assistant positions with a Member of Parliament and the Minister of State (Finance).

Andrew Casey is a native of Montreal, Quebec. After attending Loyola High School (Montreal) and St. Lawrence CEGEP (Quebec City) he graduated from Carleton University (Ottawa) with a Bachelor of Arts degree in Political Science.

Mtre. Annie Gauthier is a lawyer and a partner at the law firm BCF and specializes in business law, mergers and acquisitions, and corporate law. With over 15 years’ experience, she is one of the most respected lawyers in the field of technology and life sciences, and more specifically in the pharmaceutical industry.

Before joining BCF, Annie has practised with a nationally and internationally renowned law firm and worked on highly complex major transactions in addition to becoming one of the leading licensing experts in Canada.

Annie was also Director, Transactions at Pharmascience, the largest employer in the pharmaceutical industry in Quebec. This experience gave her inside understanding of the industry and an opportunity to conduct transactions on every continent.

Annie is actively involved with her peers and her community, and was also the President of the Montreal chapter of the Licensing Executives Society for over five years before becoming a member of the board of directors for the North American region of the organization in 2016. In 2014, she co-founded L’étoffe du succès Montréal, an organization dedicated to helping women that is affiliated with Dress for Success Worldwide.

Mtre. Gauthier graduated cum laude from McGill University with a Bachelor of Civil Law (B.C.L.) and a Bachelor of Laws (LL.B.) degrees from McGill University. She is member of the Quebec Bar since 2002.

Annie GauthierPartner and Lawyer, BCF

Mtre. Annie Gauthier is a lawyer and a partner at the law firm BCF and specializes in business law, mergers and acquisitions, and corporate law. With over 15 years’ experience, she is one of the most respected lawyers in the field of technology and life sciences, and more specifically in the pharmaceutical industry.

Before joining BCF, Annie has practised with a nationally and internationally renowned law firm and worked on highly complex major transactions in addition to becoming one of the leading licensing experts in Canada.

Annie was also Director, Transactions at Pharmascience, the largest employer in the pharmaceutical industry in Quebec. This experience gave her inside understanding of the industry and an opportunity to conduct transactions on every continent.

Annie is actively involved with her peers and her community, and was also the President of the Montreal chapter of the Licensing Executives Society for over five years before becoming a member of the board of directors for the North American region of the organization in 2016. In 2014, she co-founded L’étoffe du succès Montréal, an organization dedicated to helping women that is affiliated with Dress for Success Worldwide.

Mtre. Gauthier graduated cum laude from McGill University with a Bachelor of Civil Law (B.C.L.) and a Bachelor of Laws (LL.B.) degrees from McGill University. She is member of the Quebec Bar since 2002.

Bettina Hamelin is the President and CEO of Ontario Genomics.  Before assuming her current role in August 2017, Bettina served as Vice-President of NSERC’s Research Partnerships Directorate, where she was responsible for a range of programs designed to stimulate increased public/private sector collaboration and technology transfer by connecting the Canadian research enterprise to Canadian and global innovation stakeholders. Bettina has more than 15 years of experience in the biotech and international pharmaceutical industry as well as 10 years of academic experience as a tenured professor at the Faculty of Pharmacy at Université Laval.

Prior to joining NSERC Bettina held a variety of leadership positions at Pfizer Canada, most recently as Canadian Medical Lead, Vaccines, and Head, Strategic Research Partnerships, Western Canada. Passionate about R&D, she excels at bringing together unlikely partners to attract and leverage funds from diverse sources. She is known for pioneering novel public-private partnership models, and breaking down barriers between federal, provincial and private sector stakeholders.

Early roots in biology and chemistry (Vordiplom, Universität Kaiserslautern, Germany) have led Bettina to complete a B.Sc. in pharmacy and a Doctor of Pharmacy, both from the University of Kentucky, U.S. and an EMBA in Healthcare from the University of British Columbia, Canada.

Bettina Hamelin, OharmD, EMBAPresident and CEO, Ontario Genomics

Bettina Hamelin is the President and CEO of Ontario Genomics.  Before assuming her current role in August 2017, Bettina served as Vice-President of NSERC’s Research Partnerships Directorate, where she was responsible for a range of programs designed to stimulate increased public/private sector collaboration and technology transfer by connecting the Canadian research enterprise to Canadian and global innovation stakeholders. Bettina has more than 15 years of experience in the biotech and international pharmaceutical industry as well as 10 years of academic experience as a tenured professor at the Faculty of Pharmacy at Université Laval.

Prior to joining NSERC Bettina held a variety of leadership positions at Pfizer Canada, most recently as Canadian Medical Lead, Vaccines, and Head, Strategic Research Partnerships, Western Canada. Passionate about R&D, she excels at bringing together unlikely partners to attract and leverage funds from diverse sources. She is known for pioneering novel public-private partnership models, and breaking down barriers between federal, provincial and private sector stakeholders.

Early roots in biology and chemistry (Vordiplom, Universität Kaiserslautern, Germany) have led Bettina to complete a B.Sc. in pharmacy and a Doctor of Pharmacy, both from the University of Kentucky, U.S. and an EMBA in Healthcare from the University of British Columbia, Canada.

Bernard Lachapelle is the President of The JBL Group Inc., one of Canada’s leading pharmaceutical pricing and reimbursement consultancies, which he founded in 2000.

A recognized expert in Health Policy and Market Access as well as a passionate advocate, Bernard’s counsel is sought by industry leaders and policy makers across Canada and abroad, and he is frequently called as a speaker and as a moderator. Over the years, Bernard and his team have greatly contributed to Canadian patients’ access to medicines by solving some of the most challenging and complex pricing and reimbursement issues.

Prior to JBL, Bernard held senior executive positions with global pharmaceutical companies in Canada, acquiring extensive experience in government affairs, market access, health policy development and corporate communications as well as marketing, pricing and tendering, and human resources. Bernard also held global responsibilities in intellectual property and international trade.
A graduate in Pharmacy and Biochemistry from Laval University, Bernard has long been involved in the political process and continues to serve the community in several capacities. Bernard is a member of the Board of the Fondation québécoise du cancer and Chairman of the prestigious Prix Galien in Canada.

Bernard LachapellePresident, JBL Group Inc.

Bernard Lachapelle is the President of The JBL Group Inc., one of Canada’s leading pharmaceutical pricing and reimbursement consultancies, which he founded in 2000.

A recognized expert in Health Policy and Market Access as well as a passionate advocate, Bernard’s counsel is sought by industry leaders and policy makers across Canada and abroad, and he is frequently called as a speaker and as a moderator. Over the years, Bernard and his team have greatly contributed to Canadian patients’ access to medicines by solving some of the most challenging and complex pricing and reimbursement issues.

Prior to JBL, Bernard held senior executive positions with global pharmaceutical companies in Canada, acquiring extensive experience in government affairs, market access, health policy development and corporate communications as well as marketing, pricing and tendering, and human resources. Bernard also held global responsibilities in intellectual property and international trade.
A graduate in Pharmacy and Biochemistry from Laval University, Bernard has long been involved in the political process and continues to serve the community in several capacities. Bernard is a member of the Board of the Fondation québécoise du cancer and Chairman of the prestigious Prix Galien in Canada.

To come

Gilles Noël, Ph.D.

To come

IRICoR’s qualified personnel stand out by their scientific and commercial skills acquired in both the private and public sectors. Our multidisciplinary team combines more than 50 years of experience in project management, drug development, intellectual property, business development and venture capital.

Dr. Nadine Beauger is President and CEO of IRICoR, a Centre of Excellence in Commercialization and Research specializing in drug discovery in oncology and related areas, based at IRIC/University of Montreal. Under her leadership, Dr. Beauger has raised significant funding for her organization through federal and provincial government programs among other sources. IRICoR is rapidly expanding its project portfolio, providing academics with its tailor-made funding and support towards increasing their projects’ value and establishing strong partnerships with the private sector for innovative therapeutic solutions to reach the market faster.

Before this appointment, Dr. Beauger was Vice-President – Scientific Liaison (intellectual property (IP), academia-industry relations) at that same organization that she joined in 2009. She was instrumental at building IRICoR’s project portfolio and related IP practice and strategy, which have led to successful licensing agreements and partnerships with industry. She had brought to IRICoR over 15 years of experience in technology assessment and transfer, venture capital, IP and project portfolio management, due diligence, and clinical and biotechnological research with thorough experience in both the private and the academic sectors.

Dr. Beauger began her career as a Patent Consultant at Robic, a Montreal-based IP boutique, where she undertook drafting, prosecution and IP strategic management. She went on as Associate at VantagePoint Venture Partners (now VantagePoint Capital Partners), a leading California-headquartered venture capital firm with more than $4 billion under management. Just prior to joining IRICoR, Dr. Beauger was Business Development Manager at Paladin Labs Inc, a top specialty pharmaceutical company based in Montreal (now an Endo international company).

She holds a Ph.D. in Biomedical Sciences (Hematology and Oncology), an M.Sc. in Cellular Biopathology from Université de Montréal and a B.Sc. in Anatomy from McGill University. She also holds an MBA degree from HEC Montréal (Excellence Studentship Award and Best Speaker Award). Dr. Beauger has been an invited speaker at a number of national and international events and is a Board member of CHU Ste-Justine Foundation, ExCellThera, one of IRICoR’s spin-off companies and a clinical-stage cell and molecular medicine company and Immune BioSolutions, a Sherbrooke-based innovative biotech specialized in antibody production.

Nadine Beauger, Ph.D., MBAPresident & Chief Executive Officer

Dr. Nadine Beauger is President and CEO of IRICoR, a Centre of Excellence in Commercialization and Research specializing in drug discovery in oncology and related areas, based at IRIC/University of Montreal. Under her leadership, Dr. Beauger has raised significant funding for her organization through federal and provincial government programs among other sources. IRICoR is rapidly expanding its project portfolio, providing academics with its tailor-made funding and support towards increasing their projects’ value and establishing strong partnerships with the private sector for innovative therapeutic solutions to reach the market faster.

Before this appointment, Dr. Beauger was Vice-President – Scientific Liaison (intellectual property (IP), academia-industry relations) at that same organization that she joined in 2009. She was instrumental at building IRICoR’s project portfolio and related IP practice and strategy, which have led to successful licensing agreements and partnerships with industry. She had brought to IRICoR over 15 years of experience in technology assessment and transfer, venture capital, IP and project portfolio management, due diligence, and clinical and biotechnological research with thorough experience in both the private and the academic sectors.

Dr. Beauger began her career as a Patent Consultant at Robic, a Montreal-based IP boutique, where she undertook drafting, prosecution and IP strategic management. She went on as Associate at VantagePoint Venture Partners (now VantagePoint Capital Partners), a leading California-headquartered venture capital firm with more than $4 billion under management. Just prior to joining IRICoR, Dr. Beauger was Business Development Manager at Paladin Labs Inc, a top specialty pharmaceutical company based in Montreal (now an Endo international company).

She holds a Ph.D. in Biomedical Sciences (Hematology and Oncology), an M.Sc. in Cellular Biopathology from Université de Montréal and a B.Sc. in Anatomy from McGill University. She also holds an MBA degree from HEC Montréal (Excellence Studentship Award and Best Speaker Award). Dr. Beauger has been an invited speaker at a number of national and international events and is a Board member of CHU Ste-Justine Foundation, ExCellThera, one of IRICoR’s spin-off companies and a clinical-stage cell and molecular medicine company and Immune BioSolutions, a Sherbrooke-based innovative biotech specialized in antibody production.

An expert in both communications and journalism, Catherine Cardinal has over 20 years of experience in the field.

Since March of 2017, she has headed the communications activities of IRIC, IRICoR and Oncopole, and has many achievements to her credit in that regard, including IRIC’s rebranding, IRICoR’s increased visibility and Oncopole’s strategic positioning. As Director of Communications of those three entities, Catherine hopes to make science better-known to the general public, raise government awareness with respect to the importance of supporting research and ensure the financial sustainability of the organizations through public acknowledgement of the value of their activities.

A seasoned professional, Catherine has worked in diverse areas including culture, sports and science, and has taken on different roles, including journalist, columnist, host, producer and manager. Having worked in many distinct environments, she knows how to develop strategies adapted to various organizational realities. Passionate about challenges and strategic planning, she has dealt with complex settings such as the Olympics, film production and the media during a period of great changes. While doing so, she managed sizeable and multidisciplinary teams.

Focused on achieving clear results, Catherine is able to recognize the appropriate strategies – whether in terms of press relations, government relations or communication | marketing – that enable the organizations she works for to shine. Catherine loves her profession and enjoys sharing her knowledge. Trained in journalism, in French Studies, in arts and in sciences, she taught digital journalism at the University of Ottawa and press relations at UQAM.

Catherine CardinalManager, Communication and Media Relations

An expert in both communications and journalism, Catherine Cardinal has over 20 years of experience in the field.

Since March of 2017, she has headed the communications activities of IRIC, IRICoR and Oncopole, and has many achievements to her credit in that regard, including IRIC’s rebranding, IRICoR’s increased visibility and Oncopole’s strategic positioning. As Director of Communications of those three entities, Catherine hopes to make science better-known to the general public, raise government awareness with respect to the importance of supporting research and ensure the financial sustainability of the organizations through public acknowledgement of the value of their activities.

A seasoned professional, Catherine has worked in diverse areas including culture, sports and science, and has taken on different roles, including journalist, columnist, host, producer and manager. Having worked in many distinct environments, she knows how to develop strategies adapted to various organizational realities. Passionate about challenges and strategic planning, she has dealt with complex settings such as the Olympics, film production and the media during a period of great changes. While doing so, she managed sizeable and multidisciplinary teams.

Focused on achieving clear results, Catherine is able to recognize the appropriate strategies – whether in terms of press relations, government relations or communication | marketing – that enable the organizations she works for to shine. Catherine loves her profession and enjoys sharing her knowledge. Trained in journalism, in French Studies, in arts and in sciences, she taught digital journalism at the University of Ottawa and press relations at UQAM.

Jasmine Dorcent joined IRICoR in 2018 as a Financial Management Officer. Since then, she has handled accounting operations and is in charge of budget control and the preparation of financial statements. She also takes part in improving processes and implementing new procedures.

Mrs. Dorcent worked as a Financial Officer for the Public Curator, where she was in charge of budget control and ensured the conformity of tax returns. She also worked as an administrative technician in accounting at the Centre Hospitalier de l’Université de Montréal, where she was responsible for accounts receivable. Just before joining IRICoR, she carried out tax audits on individuals for Revenu Québec.

Jasmine Dorcent has a bachelor’s degree in accounting sciences from the Université du Québec à Montréal and is currently a candidate to become a CPA.

Jasmine DorcentFinancial Management Officer

Jasmine Dorcent joined IRICoR in 2018 as a Financial Management Officer. Since then, she has handled accounting operations and is in charge of budget control and the preparation of financial statements. She also takes part in improving processes and implementing new procedures.

Mrs. Dorcent worked as a Financial Officer for the Public Curator, where she was in charge of budget control and ensured the conformity of tax returns. She also worked as an administrative technician in accounting at the Centre Hospitalier de l’Université de Montréal, where she was responsible for accounts receivable. Just before joining IRICoR, she carried out tax audits on individuals for Revenu Québec.

Jasmine Dorcent has a bachelor’s degree in accounting sciences from the Université du Québec à Montréal and is currently a candidate to become a CPA.

Hélène Grangé joined the IRICoR team in September of 2020 as Contract and Licensing Officer. Her experience in the field, both in academia and the pharmaceutical industry is a great asset to IRICoR.

She earned a M.Sc. in Cell Biology from the Université de Nantes and a Professional Master’s degree in Project Management from the Institut d’administration des entreprises. For the last 15 years, she has worked in the field of valorization of university innovations at the Université de Montréal. She has helped negotiate several collaboration and license agreements, mainly in the life sciences field.

Hélène was also very involved in entrepreneurship by being part of the management committee of the Centre d’entrepreneuriat Poly-UdeM and in the strategic planning on entrepreneurship of the Université de Montréal. That initiative resulted in creating an entrepreneurship coordination position at the UdeM.

Previously, Hélène Grangé was a consultant at Parteurop Developpement where she worked in the strategic analysis of companies specializing in vaccines. She also was a consultant for Gestion Valeo, and as a valorization advisor with investigators in hospital research centres.

Hélène GrangéContracts and Licensing Officer

Hélène Grangé joined the IRICoR team in September of 2020 as Contract and Licensing Officer. Her experience in the field, both in academia and the pharmaceutical industry is a great asset to IRICoR.

She earned a M.Sc. in Cell Biology from the Université de Nantes and a Professional Master’s degree in Project Management from the Institut d’administration des entreprises. For the last 15 years, she has worked in the field of valorization of university innovations at the Université de Montréal. She has helped negotiate several collaboration and license agreements, mainly in the life sciences field.

Hélène was also very involved in entrepreneurship by being part of the management committee of the Centre d’entrepreneuriat Poly-UdeM and in the strategic planning on entrepreneurship of the Université de Montréal. That initiative resulted in creating an entrepreneurship coordination position at the UdeM.

Previously, Hélène Grangé was a consultant at Parteurop Developpement where she worked in the strategic analysis of companies specializing in vaccines. She also was a consultant for Gestion Valeo, and as a valorization advisor with investigators in hospital research centres.

Dr. Steven Klein is IRICoR’s VP, Business Development. With over 20 years of experience in a variety of fields, including oncology, vaccines, and CNS-related indications, Dr Klein bring an invaluable knowledge of the private sector and of private-public initiatives.

At IRICoR since 2011, he has successfully negotiated and managed agreements with a variety of private sector partners, including BMS, Ipsen, Abbvie, Merck, Pfizer, AstraZeneca, Domain Therapeutics, Encycle Therapeutics, and Medigene, as well as IRICoR’s alliances with its CECR and academic partners, including Toronto Innovation Acceleration Partners (formely MaRS Innovation), CCRM, and AdMare.  Dr. Klein also represented IRICoR in creating its recent spin-off companies ExCellThera and SpecificiT.

Prior to joining IRICoR, Dr. Klein held Business Development roles at Labopharm, BELLUS Health, Neurochem, and the Canadian Network for Vaccines and Immunotherapeutics (CANVAC) where he negotiated and concluded a wide range of licensing and co-development agreements, covering both products and technologies, with industry leaders such as Roche, GSK, Grunenthal, Sanofi Pasteur, Becton Dickinson, and Nippon Shinyaku.

Dr. Klein holds a B.Sc. (Honors) in Chemistry from Concordia University, a Ph.D. in Experimental Medicine from McGill University, and an MBA from Queen’s University.

 

0002_SKlein
Steven J. Klein, Ph.D., MBAVice-President, Business Development

Dr. Steven Klein is IRICoR’s VP, Business Development. With over 20 years of experience in a variety of fields, including oncology, vaccines, and CNS-related indications, Dr Klein bring an invaluable knowledge of the private sector and of private-public initiatives.

At IRICoR since 2011, he has successfully negotiated and managed agreements with a variety of private sector partners, including BMS, Ipsen, Abbvie, Merck, Pfizer, AstraZeneca, Domain Therapeutics, Encycle Therapeutics, and Medigene, as well as IRICoR’s alliances with its CECR and academic partners, including Toronto Innovation Acceleration Partners (formely MaRS Innovation), CCRM, and AdMare.  Dr. Klein also represented IRICoR in creating its recent spin-off companies ExCellThera and SpecificiT.

Prior to joining IRICoR, Dr. Klein held Business Development roles at Labopharm, BELLUS Health, Neurochem, and the Canadian Network for Vaccines and Immunotherapeutics (CANVAC) where he negotiated and concluded a wide range of licensing and co-development agreements, covering both products and technologies, with industry leaders such as Roche, GSK, Grunenthal, Sanofi Pasteur, Becton Dickinson, and Nippon Shinyaku.

Dr. Klein holds a B.Sc. (Honors) in Chemistry from Concordia University, a Ph.D. in Experimental Medicine from McGill University, and an MBA from Queen’s University.

 

Since joining IRICoR in 2009 as Project Manager, Alix Molinier has been responsible of the financial and administrative tasks, monitoring IRICoR’s portfolio projects. She also actively contributes to the development of follow-up and analysis tools for internal uses, and to the gathering of competitive intelligence around portfolio projects.

Ms. Molinier has over 12 years of experience in project management, with a specific focus on biotechnology start-up companies both from a scientific and a human resource standpoint. Alix began her career as an Analyst and Project Officer at Grand Luminy Incubator, a Marseille-based strategic support and logistics facility that assists in the creation of biotechnology businesses, where she undertook competitive intelligence analysis for the organization’s clients. She continued performing competitive intelligence analysis as an Analyst at CEIM (Centre d’entreprises et d’innovation de Montréal), an incubator of new technology companies. Just prior to joining IRICoR, she was Project Officer at Pharmabio Development, a Work Force sectoral Committee for pharmaceutical and biotechnology companies.

Ms. Molinier led her Engineering and Master II curricula in parallel. She holds a double Diploma in Project Management specializing in Biotechnology from Euromed Marseille – Management School and from ESIL (École Supérieure d’Ingénieurs de Luminy).

0004_AMolinier
Alix MolinierProject Manager

Since joining IRICoR in 2009 as Project Manager, Alix Molinier has been responsible of the financial and administrative tasks, monitoring IRICoR’s portfolio projects. She also actively contributes to the development of follow-up and analysis tools for internal uses, and to the gathering of competitive intelligence around portfolio projects.

Ms. Molinier has over 12 years of experience in project management, with a specific focus on biotechnology start-up companies both from a scientific and a human resource standpoint. Alix began her career as an Analyst and Project Officer at Grand Luminy Incubator, a Marseille-based strategic support and logistics facility that assists in the creation of biotechnology businesses, where she undertook competitive intelligence analysis for the organization’s clients. She continued performing competitive intelligence analysis as an Analyst at CEIM (Centre d’entreprises et d’innovation de Montréal), an incubator of new technology companies. Just prior to joining IRICoR, she was Project Officer at Pharmabio Development, a Work Force sectoral Committee for pharmaceutical and biotechnology companies.

Ms. Molinier led her Engineering and Master II curricula in parallel. She holds a double Diploma in Project Management specializing in Biotechnology from Euromed Marseille – Management School and from ESIL (École Supérieure d’Ingénieurs de Luminy).

Ms. Ferima Sanogo began her duties at IRICoR in September of 2019 as a junior project manager. Before joining IRICoR, Ms. Sanogo worked at Maelstrom Research, a scientific platform based at the Research Institute of the McGill University Health Centre (RI-MUHC), specializing in method and software development. She was in charge of the day-to-day management of operations, the quality assurance of projects and the administrative coordination of the research group.

She began her career as a clinical research assistant at the Unité de Recherche Clinique de l’Est Parisien where she handled projects that included pediatric onco-hematology. She then continued her career as a research agent responsible for quality control with the Public Project Population in Genomics (P3G), a non-profit organization. Thereafter she worked with the Clinical Research Group – Pediatric Intensive Care Unit of the CHU Sainte-Justine. These experiences, mainly in clinical research, focused on the monitoring and quality assurance of projects, internal audit management, regulatory follow-up of projects and the development of documents related to the studies. She also contributed to developing performance indicators.

Ms. Sanogo earned a Master’s in Project Management from ESG UQAM, as well as a Master’s in Health Administration from Université Paris 5. She also carried out specialized inter-university training in clinical research at Université Paris 7.

Ferima Sanogo, M.Sc., MGP Junior Project manager

Ms. Ferima Sanogo began her duties at IRICoR in September of 2019 as a junior project manager. Before joining IRICoR, Ms. Sanogo worked at Maelstrom Research, a scientific platform based at the Research Institute of the McGill University Health Centre (RI-MUHC), specializing in method and software development. She was in charge of the day-to-day management of operations, the quality assurance of projects and the administrative coordination of the research group.

She began her career as a clinical research assistant at the Unité de Recherche Clinique de l’Est Parisien where she handled projects that included pediatric onco-hematology. She then continued her career as a research agent responsible for quality control with the Public Project Population in Genomics (P3G), a non-profit organization. Thereafter she worked with the Clinical Research Group – Pediatric Intensive Care Unit of the CHU Sainte-Justine. These experiences, mainly in clinical research, focused on the monitoring and quality assurance of projects, internal audit management, regulatory follow-up of projects and the development of documents related to the studies. She also contributed to developing performance indicators.

Ms. Sanogo earned a Master’s in Project Management from ESG UQAM, as well as a Master’s in Health Administration from Université Paris 5. She also carried out specialized inter-university training in clinical research at Université Paris 7.

Clara Scattolin joined the IRICoR team in March of 2020 as a Junior Project Manager. She is in charge of coordinating all ad hoc projects, assisting in the drafting of administrative reports related to reporting to funding agencies and setting up events associated with entrepreneurial initiatives.

Ms. Scattolin is excited about beginning her professional career at IRICoR. Along her academic path, she acquired experience as a project manager as part of a team of pharmacists at Sainte-Justine Hospital. Among other things, she coordinated a large team of health professionals for the purpose of writing the 3rd edition of the reference manual titled: “Grossesse et allaitement : guide thérapeutique”.

Extremely involved and committed, Ms. Scattolin demonstrated great student involvement within the Faculty of Pharmacy of the Université de Montréal: she was President of the Student Association, a member of the faculty committees, a teaching assistant and a pharmacoepidemiological intern. Ms. Scattolin was appointed ambassador of the Faculty of Pharmacy Centennial celebration, as she is one of the most influential people in the Faculty over the last 100 years. She has also received other excellence and leadership awards.

Clara has a degree in Biopharmaceutical Sciences from the Université de Montréal and a post-graduate degree in Business Administration from HEC Montréal.

Clara Scattolin, DESSJunior Project manager

Clara Scattolin joined the IRICoR team in March of 2020 as a Junior Project Manager. She is in charge of coordinating all ad hoc projects, assisting in the drafting of administrative reports related to reporting to funding agencies and setting up events associated with entrepreneurial initiatives.

Ms. Scattolin is excited about beginning her professional career at IRICoR. Along her academic path, she acquired experience as a project manager as part of a team of pharmacists at Sainte-Justine Hospital. Among other things, she coordinated a large team of health professionals for the purpose of writing the 3rd edition of the reference manual titled: “Grossesse et allaitement : guide thérapeutique”.

Extremely involved and committed, Ms. Scattolin demonstrated great student involvement within the Faculty of Pharmacy of the Université de Montréal: she was President of the Student Association, a member of the faculty committees, a teaching assistant and a pharmacoepidemiological intern. Ms. Scattolin was appointed ambassador of the Faculty of Pharmacy Centennial celebration, as she is one of the most influential people in the Faculty over the last 100 years. She has also received other excellence and leadership awards.

Clara has a degree in Biopharmaceutical Sciences from the Université de Montréal and a post-graduate degree in Business Administration from HEC Montréal.

Audrey Segret joined IRICoR in 2015 as Project Manager, and her responsibilities include tasks such as recruiting innovative scientific projects for potential investment, and regularly following up and reporting the progress of portfolio projects according to their milestones. She has also developed key analytics tools for project management within the organization.

Dr. Segret brings over 8 years of experience in project management to IRICoR. Prior to joining IRICoR, she contributed to business development activities at Boralex by ensuring coordination with internal departments (development, regulatory affairs, financial and operations on sites), executive level and partners. Prior to joining Boralex, Audrey was a scientific consultant at Alma Consulting Group (France and Canada) where she was in charge of managing a portfolio of clients involved in a number of research and development activities. For each project, she identified ways to secure a claim process (SR&ED) and to review reports submitted to government institutions. Audrey provided scientific and financial support to more than 200 innovative business projects.

Dr. Segret holds a Ph.D. in Life Sciences (speciality: cardiovascular pharmacology) and her research project was realized in the UMR-CNRS 8162 Unit (Paris V – France) on the «Implication of the CXCL12 chimiokine and its CXCR4 and CXCR7 receptors in cardiac physiology and physiopathology».

0003_ASegret
Audrey Segret, Ph.D.Project manager

Audrey Segret joined IRICoR in 2015 as Project Manager, and her responsibilities include tasks such as recruiting innovative scientific projects for potential investment, and regularly following up and reporting the progress of portfolio projects according to their milestones. She has also developed key analytics tools for project management within the organization.

Dr. Segret brings over 8 years of experience in project management to IRICoR. Prior to joining IRICoR, she contributed to business development activities at Boralex by ensuring coordination with internal departments (development, regulatory affairs, financial and operations on sites), executive level and partners. Prior to joining Boralex, Audrey was a scientific consultant at Alma Consulting Group (France and Canada) where she was in charge of managing a portfolio of clients involved in a number of research and development activities. For each project, she identified ways to secure a claim process (SR&ED) and to review reports submitted to government institutions. Audrey provided scientific and financial support to more than 200 innovative business projects.

Dr. Segret holds a Ph.D. in Life Sciences (speciality: cardiovascular pharmacology) and her research project was realized in the UMR-CNRS 8162 Unit (Paris V – France) on the «Implication of the CXCL12 chimiokine and its CXCR4 and CXCR7 receptors in cardiac physiology and physiopathology».

Jean-Louis Brochu is a Pharmaceutical Intellectual Property expert with 10 years experience in providing International IP landscapes, freedom-to-operate, infringement and validity opinions on several pharmaceutical products.  He was the Lead Intellectual Property Scientist at Pharmascience, a leading Canadian generic pharmaceutical company.  Jean-Louis supported IP generation for the Innovative branch Pendopharm and provided IP support in all aspect of drug development; from idea generation, product development, submission, product launch to post-launch IP/litigation activities.

Prior to Pharmascience, Jean-Louis worked as a synthetic organic chemist for 5 years at the National Research Council Canada (NRCC), Painceptor Pharma and Sussex Research Laboratories in Ottawa.  Jean-Louis is a registered chemist with l’ordre des chimistes du Québec, has a B.Sc. in Biopharmaceutical Sciences – Medicinal Chemistry and an M.Sc. in Organic Chemistry, both at the University of Ottawa.  He was also a member of the Canadian Generic Pharmaceutical Association IP committee.

Jean-Louis Brochu, M.Sc.Senior Intellectual Property Manager

Jean-Louis Brochu is a Pharmaceutical Intellectual Property expert with 10 years experience in providing International IP landscapes, freedom-to-operate, infringement and validity opinions on several pharmaceutical products.  He was the Lead Intellectual Property Scientist at Pharmascience, a leading Canadian generic pharmaceutical company.  Jean-Louis supported IP generation for the Innovative branch Pendopharm and provided IP support in all aspect of drug development; from idea generation, product development, submission, product launch to post-launch IP/litigation activities.

Prior to Pharmascience, Jean-Louis worked as a synthetic organic chemist for 5 years at the National Research Council Canada (NRCC), Painceptor Pharma and Sussex Research Laboratories in Ottawa.  Jean-Louis is a registered chemist with l’ordre des chimistes du Québec, has a B.Sc. in Biopharmaceutical Sciences – Medicinal Chemistry and an M.Sc. in Organic Chemistry, both at the University of Ottawa.  He was also a member of the Canadian Generic Pharmaceutical Association IP committee.

Mrs. Elizabeth Wong joined the IRICoR team 2019 as a Business Development Analyst to support its commercialization efforts.

Prior to joining IRICoR, she was a Business Development Strategist at Accreon, providing guidance for the strategic roadmap and supporting the Sales and Marketing team in engaging biopharmaceutical clients.

Her experience includes independent consulting mandates and work on projects and strategic initiatives in the pharmaceutical, health technology, government and academic sectors. As a member of multiple cross-functional teams at Merck, she piloted new technologies and contributed to the discovery and development of novel medications for human health that have led to several regulatory filings for the Canadian and international markets.

Elizabeth holds a B.Sc. (Honors) in Microbiology and Immunology from McGill University and is a PMP-certified project manager.

Elizabeth Wong, B.Sc., PMPAnalyst, Business Development

Mrs. Elizabeth Wong joined the IRICoR team 2019 as a Business Development Analyst to support its commercialization efforts.

Prior to joining IRICoR, she was a Business Development Strategist at Accreon, providing guidance for the strategic roadmap and supporting the Sales and Marketing team in engaging biopharmaceutical clients.

Her experience includes independent consulting mandates and work on projects and strategic initiatives in the pharmaceutical, health technology, government and academic sectors. As a member of multiple cross-functional teams at Merck, she piloted new technologies and contributed to the discovery and development of novel medications for human health that have led to several regulatory filings for the Canadian and international markets.

Elizabeth holds a B.Sc. (Honors) in Microbiology and Immunology from McGill University and is a PMP-certified project manager.

Lizanne Boily joined IRICoR in 2015 as IRICoR’s administrative assistant. Prior to joining IRICoR, Lizanne worked at Versant Partners, a boutique investment bank specialized in biotechnology, which offered equity underwriting, private placement, and mergers and acquisitions advisory services. During that time, she contributed to the support in the administration of project management, accounting, human resources and compliance. She also worked as executive assistant to the Research Director at National Bank Financial and as a laboratory technician in chemistry at both universities and private companies. With more than 20 years of experience in the financial sector, Lizanne brings her knowledge in facilitating the coordination of different administrative tasks and responsibilities and ensures work efficiency among team members.

Lizanne holds a Bachelor degree in Sciences from Université de Montréal, a certification in Human Resources Management at HEC, and a Canadian Securities Course certification.

0007_LBoily
Lizanne BoilyClerical Technician

Lizanne Boily joined IRICoR in 2015 as IRICoR’s administrative assistant. Prior to joining IRICoR, Lizanne worked at Versant Partners, a boutique investment bank specialized in biotechnology, which offered equity underwriting, private placement, and mergers and acquisitions advisory services. During that time, she contributed to the support in the administration of project management, accounting, human resources and compliance. She also worked as executive assistant to the Research Director at National Bank Financial and as a laboratory technician in chemistry at both universities and private companies. With more than 20 years of experience in the financial sector, Lizanne brings her knowledge in facilitating the coordination of different administrative tasks and responsibilities and ensures work efficiency among team members.

Lizanne holds a Bachelor degree in Sciences from Université de Montréal, a certification in Human Resources Management at HEC, and a Canadian Securities Course certification.


© 2008-2020 IRICoR